menu
    • menu
    [{"orgOrder":0,"company":"Cleave Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CB-5339","moa":"Valosin-containing protein p97 (VCP)","graph1":"Oncology","graph2":"Phase I","graph3":"Cleave Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cleave Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cleave Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cleave Therapeutics","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CB-5339 Tosylate","moa":"VCP\/p97","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cleave Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cleave Therapeutics \/ Cleave Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Cleave Therapeutics \/ Cleave Therapeutics"},{"orgOrder":0,"company":"Cleave Therapeutics","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"CB-5339 Tosylate","moa":"VCP\/p97","graph1":"Oncology","graph2":"Phase I","graph3":"Cleave Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cleave Therapeutics \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Cleave Therapeutics \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"Cleave Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CB-5339 Tosylate","moa":"VCP\/p97","graph1":"Oncology","graph2":"Phase I","graph3":"Cleave Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cleave Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cleave Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cleave Therapeutics","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"CB-5339 Tosylate","moa":"VCP\/p97","graph1":"Oncology","graph2":"Phase I","graph3":"Cleave Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Cleave Therapeutics \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Cleave Therapeutics \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"Cleave Therapeutics","sponsor":"Eikon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Cleave Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleave Therapeutics \/ Eikon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cleave Therapeutics \/ Eikon Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Cleave Therapeutics

    Menu

    Cleave Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cleave Therapeutics

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Cleave Therapeutics

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CB-5339 Tosylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : CASI Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB...

                            Details : Through the acquisition, CASI gains global rights to the Cleave's clinical asset, CB-5339 tosylate, an oral, second-generation, small molecule valosin-containing protein (VCP)/p97 inhibitor, in patients with acute myeloid leukemia and myelodysplastic syn...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 20, 2023

                            Lead Product(s) : CB-5339 Tosylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : CASI Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cleave Therapeutics

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Cleave Therapeutics

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Eikon Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets

                            Details : Through the acquisition, Eikon gains Cleave’s preclinical assets, including a large chemical library spanning multiple targets in the AAA (ATPases Associated with diverse cellular Activities) family of ATPases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 20, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Eikon Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cleave Therapeutics

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Cleave Therapeutics

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CB-5339 Tosylate

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : CASI Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Casi Pharmaceuticals and Cleave Therapeutics Announce Clinical Trial Application Approval for CB-5339 in Patie...

                            Details : CB-5339 is an oral second-generation, small molecule VCP/p97 inhibitor, and is currently in Phase 1 clinical trial in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and myeloproliferative neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 06, 2023

                            Lead Product(s) : CB-5339 Tosylate

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : CASI Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cleave Therapeutics

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Cleave Therapeutics

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CB-5339 Tosylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : CASI Pharmaceuticals

                            Deal Size : $85.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Cleave Therapeutics Licenses First-in-Class VCP/P97 Inhibitor CB-5339 To CASI Pharmaceuticals For Greater Chin...

                            Details : Under the terms of the agreement, Cleave and CASI will develop CB-5339 in both hematological malignancies and solid tumors, with CASI responsible for development and commercialization in China and associated markets.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $5.5 million

                            March 08, 2021

                            Lead Product(s) : CB-5339 Tosylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : CASI Pharmaceuticals

                            Deal Size : $85.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cleave Therapeutics

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Cleave Therapeutics

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CB-5339 Tosylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cleave Therapeutics Announces Commencement of a Phase 1 Clinical Study of CB-5339 for Acute Myeloid Leukemia a...

                            Details : First patient has been dosed with CB-5339 in a Phase 1 clinical trial of patients with relapsed/refractory acute myeloid leukemia (AML) or relapsed/refractory intermediate or high-risk myelodysplastic syndrome (MDS).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 28, 2020

                            Lead Product(s) : CB-5339 Tosylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cleave Therapeutics

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Cleave Therapeutics

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CB-5339

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome

                            Details : CB-5339 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 27, 2020

                            Lead Product(s) : CB-5339

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth